The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study

[1]  P. Geusens,et al.  Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study , 2015, Osteoporosis International.

[2]  P. Muntner,et al.  Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries , 2014, BMC Musculoskeletal Disorders.

[3]  M. Brookhart,et al.  Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women , 2013, International journal of general medicine.

[4]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[5]  K. Kostev,et al.  Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. , 2012, International journal of clinical pharmacology and therapeutics.

[6]  T. N. Harrison,et al.  Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates , 2012, The Annals of pharmacotherapy.

[7]  J. Adams,et al.  Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. , 2012, Bone.

[8]  C. McHorney,et al.  Frequency of and reasons for medication non‐fulfillment and non‐persistence among American adults with chronic disease in 2008 , 2011, Health expectations : an international journal of public participation in health care and health policy.

[9]  A. Regnault,et al.  Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women , 2011, Osteoporosis International.

[10]  M. Hochberg,et al.  Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study , 2010, Current medical research and opinion.

[11]  A. Tosteson,et al.  Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ , 2010, Osteoporosis International.

[12]  E. Siris.  Clinical issues with bisphosphonate therapy for osteoporosis. Introduction. , 2009, The American journal of medicine.

[13]  G. de Pouvourville,et al.  Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. , 2008, Clinical therapeutics.

[14]  S. Rietbrock,et al.  Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  J. Cauley,et al.  Bone mineral density changes during the menopause transition in a multiethnic cohort of women. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  S. Andrade,et al.  Consequences of poor compliance with bisphosphonates. , 2007, Bone.

[17]  D. Gold,et al.  A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis , 2007, Current medical research and opinion.

[18]  J. Cramer,et al.  The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. , 2006, Clinical therapeutics.

[19]  R. Herings,et al.  Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study* , 2006, Current medical research and opinion.

[20]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[21]  C. Cooper,et al.  Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey , 2006, Osteoporosis International.

[22]  B. Ettinger,et al.  Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.

[23]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[24]  R. Herings,et al.  Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. , 2006, Clinical therapeutics.

[25]  G. Herrero-Beaumont,et al.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. , 2004, Clinical therapeutics.

[26]  P. Geusens,et al.  Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada. , 2015, Clinical and experimental rheumatology.

[27]  M. Intorcia,et al.  GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates , 2011, Osteoporosis International.